4篇
您的检索式：作者名="Roberto Iacovelli"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of MGMT as biomarker in colorectal cancer显示文摘O6-methylguanine DNA methyltransferase(MGMT) gene promoter methylation plays an important role in colorectal carcinogenesis, occurring in about 30%-40% of metastatic colorectal cancer. Its prognostic role has not been defined yet, but loss of expression of MGMT, which is secondary to gene promoter methylation, results in an interesting high response to alkylating agents such as dacarbazine and temozolomide. In a phase 2 study on heavily pre-treated patients with MGMT methylated metastatic colorectal cancer, temozolomide achieved about 30% of disease control rate. Activating mutations of RAS or BRAF genes as well as mismatch repair deficiency may represent mechanisms of resistance to alkylating agents, but a dose-dense schedule of temozolomide may potentially restore sensitivity in RAS-mutant patients. Further development of temozolomide in MGMT methylated colorectal cancer includes investigation of synergic combinations with other agents such as fluoropyrimidines and research for additional biomarkers, in order to better define the role of temozolomide in the treatment of individual patients. | Alessandro Inno Giuseppe Fanetti Maria Di Bartolomeo Stefania Gori Claudia Maggi Massimo Cirillo Roberto Iacovelli Federico Nichetti Antonia Martinetti Filippo de Braud Ilaria Bossi Filippo Pietrantonio | 2014 | World Journal of Clinical Cases2014，2，12： | 10 |
| 2 | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta‐analysis of clinical trials显示文摘 | Matteo Santoni Alessandro Conti Ugo De Giorgi Roberto Iacovelli Francesco Pantano Luciano Burattini Giovanni Muzzonigro Rossana Berardi Daniele Santini Stefano Cascinu | 2014 | Int. J. Cancer2014，，： | 2 |
| 3 | Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials显示文摘 | Matteo Santoni Alessandro Conti Francesco Massari Giorgio Arnaldi Roberto Iacovelli Mimma Rizzo Ugo Giorgi Laura Trementino Giuseppe Procopio Giampaolo Tortora Stefano Cascinu | 2015 | Int. J. Cancer2015，，： | 1 |
| 4 | First-line pazopanib in patients with advanced non-clear cell renal carcinoma:An Italian case series显示文摘BACKGROUND Non-clear cell(ncc)metastatic renal-cell carcinoma(RCC)has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart.New systemic combination therapies have emerged for metastatic RCC(mRCC),but the pivotal phase III trials excluded patients with nccRCC,which constitute about 30%of metastatic RCC cases.AIM To provide a piece of real-life evidence on the use of pazopanib in this patient subgroup.METHODS The present study is a multicenter retrospective observational analysis aiming to assess the activity,efficacy,and safety of pazopanib as first-line therapy for advanced nccRCC patients treated in a real-life setting.RESULTS Overall,48 patients were included.At the median follow-up of 40.6 mo,the objective response rate was 27.1%,the disease control rate was 83.3%,and the median progression-free survival and overall survival were 12.3(95%confidence interval[CI]:3.6-20.9)and 27.7(95%CI:18.2-37.1)mo,respectively.Grade 3 adverse events occurred in 20%of patients,and no grade 4 or 5 toxicities were found.CONCLUSION Pazopanib should be considered as a good first-line option for metastatic RCC with variant histology. | Sebastiano Buti Melissa Bersanelli Francesco Massari Ugo De Giorgi Orazio Caffo Gaetano Aurilio Umberto Basso Giacomo Carteni Claudia Caserta Luca Galli Francesco Boccardo Giuseppe Procopio Gaetano Facchini Giuseppe Fornarini Alfredo Berruti Elena Fea Emanuele Naglieri Fausto Petrelli Roberto Iacovelli Camillo Porta Alessandra Mosca | 2021 | World Journal of Clinical Oncology2021，12，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员